Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy
Glomerular Diseases – 2025
Search Results
Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Resource type
Resource type
×Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Sort by
Publications
Results54
Targeting Endothelin and Angiotensin Pathways for Kidney Function Preservation in Glomerular Disease
European Medical Journal – 2026
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated Focal Segmental Glomerulosclerosis Enrolled in the DUPLEX Trial
Clinical Journal of the American Society of Nephrology – 2025
Association Between Complete Proteinuria Remission and Kidney Function in Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy
Clinical Journal of the American Society of Nephrology – 2025
KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
Kidney International – 2025
Not funded by Travere
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis
Kidney Medicine – 2022
Congress materials
Results123
Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti-inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study
2025
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: An Interim Analysis of the SPARTAN Trial Evaluating Efficacy and Cardiovascular Risk Variables
International Symposium on IgA Nephropathy (IIgANN) – 2025
Patients With Focal Segmental Glomerulosclerosis (FSGS) Reach Proteinuria <0.7 g/g More Often With Sparsentan vs Irbesartan in DUPLEX: Implications for Kidney Failure Risk
American Society of Nephrology (ASN) Kidney Week – 2025
Patients With Focal Segmental Glomerulosclerosis (FSGS) Reach Proteinuria <0.7 g/g More Often With Sparsentan vs Irbesartan in DUPLEX: Implications for Kidney Failure Risk
American Society of Nephrology (ASN) Kidney Week – 2025
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy
American Society of Nephrology (ASN) Kidney Week – 2025
Impact of Histology on Efficacy of Sparsentan Therapy in IgA Nephropathy: Central Biopsy Review of Patients in the PROTECT Trial
American Society of Nephrology (ASN) Kidney Week – 2025
Events
Results19
Upcoming
October 21–25, 2026 – Denver, CO
American Society of Nephrology (ASN) Kidney Week 2026
Coming soon
Upcoming
August 3–7, 2026 – Maui, HI
GlomCon Hawaii 2026
Upcoming
November 12–16, 2026 – Galveston, TX
International Society of Glomerular Disease (ISGD) Clinical Trials Summit 2026
Upcoming
June 20–24, 2026 – Boston, MA
American Transplant Congress (ATC) 2026
Upcoming
June 3–6, 2026 – Glasgow, Scotland
63rd European Renal Association (ERA) Congress 2026
Upcoming
May 7–10, 2026 – New Orleans, LA
National Kidney Foundation (NKF) 2026 Spring Clinical Meetings
Downloadable resources
Results7
KDIGO 2025 Infographic
FILSPARI US PI
FSGS Mechanism of Action
Travere Infographic-Overview of data on concomitant use of sparsentan and SGLT2i in IgA nephropathy
Travere Therapeutics – PROTECT 2-year findings Infographic Dec 2024
Kohan Infographic
Abstracts
Results48
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety Visual Abstract
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Sparsentan (SPAR) vs Irbesartan (IRB) in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial